0      0

2022 AABB Annual Meeting

AM22-SN16-L - AM22-SN16-L: Managing Challenging MNC/HPC Cell Collections – Quality & Quantity (Live)

Oct 2, 2022 1:30pm ‐ Oct 2, 2022 2:30pm

Credits: None available.


With the introduction of current and up-and-coming novel cellular therapeutics, Apheresis collection facilities became center stage as the manufacturer of the starting material through the common pathway of the collection procedure. Workloads for collection facilities have been significantly increased, including additional quality requirements such as audits & accommodating large number of clinical trials. Collection facilities are now facing challenges to ensure continued compliance in the cellular therapy arena. The speakers will share the perspective on this crucial topic and how these challenges can be mitigated. Different efforts in the field to standardize approaches will be shared with the audience as well as dealing with challenging collection scenarios such as patients with complex cardiac history. Attendees will benefit from sharing experiences of the panelists as well as generate ideas and solutions for future success of the field as we move forward with more Cellular Therapy products (commercial & clinical trials). Understanding the challenges around these collections, including management of complex patients’ population, will benefit the field as we bring the product from bench to bedside.

Learning Objectives:
  • Describe challenges associated with maintaining trained, competent collection staffing as it relates to the expansion of the new cellular therapies.
  • Discuss how best to ease the burden for Apheresis collection facilities dealing with starting materials both in commercial and clinical trial phase
  • Identify solutions to achieve and maintain compliance throughout standardized approaches, decrease duplications (e.g., audits), develop tools, and systems that help Collection facilities and downstream effects (SCL; manufacturers) dealing with starting materials.
  • Describe the management of unique patient populations that need to be collected such as patients with complex cardiac histories.




  • Joseph Schwartz, MD, MPH : Nothing to Disclose
  • Ian Baine : Nothing to Disclose
  • Suzanne Arinsburg, DO : Nothing to Disclose


Credits: None available.

You must be logged in and own this session in order to post comments.